Held by 8 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying8 funds opened new positions. Next phase2 readout (NDV01 intravesical controlled release formulation of gemcitabine and docetaxel): Aug 2025. Short interest: 13.4% of float.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.